Annovis Bio Inc. announced the addition of four accomplished professionals to its executive team. Mark White Appointed Chief Business Officer: Currently a member of Board of Directors, Mark White brings a wealth of global pharmaceutical marketing, business development, and sales experience to his new role as Chief Business Officer. Throughout his career, Mr. White has held positions of increasing responsibility at Pfizer, Bracco, Abbott, and Bayer.

In his last role at Pfizer, he served as Vice President of Worldwide Marketing, overseeing global new product development, business development, and in-line marketing for the Inflammation Therapeutic Area. Mark holds Bachelor?s and Master?s degrees from the University of Missouri and an MBA from the University of Chicago Booth School of Business. Alexander Morin, Ph.D., Appointed Director of Strategic Communications: Dr. Morin brings extensive experience at the intersection of science and communications within the biopharmaceutical industry.

He has previously held the position of account executive at a boutique public relations firm, where he enhanced visibility and corporate communications strategies for a diverse range of clients, including early-to-late stage biotech companies, non-profit organizations, and large pharma. Prior to his PR role, Dr. Morin served as a consultant scientist at a CRO, where he was instrumental in designing studies for drug candidates. He earned his Ph.D. in Neuroscience from the Open University (UK), focusing his research on drug development for chronic traumatic brain injury.

Hilda Maibach appointed Senior Vice President of Statistics: Ms. Maibach brings more than 30 years of experience in all aspects of clinical and observational studies in Oncology, Infectious Disease, Metabolic disorders and Central Nervous System Disorders. Her work has supported industry, NIH and DOD funded clinical trials with a focus on improving measurement sensitivity and innovating clinical trial design, data acquisition and management. She worked to incorporate real-world evidence along with bioinformatics tools into clinical study design management to reduce costs and improve outcome reliability.

Ms. Maibach served as research faculty at Emory and Stanford Universities, and Centers for Disease Control (CDC) as a statistician for CLIA. She holds an MSc in Statistics from Stanford University. Blake Jensen appointed Head of Quality: Blake Jensen has over 20 years of experience in Quality within contract service providers and emerging biopharma companies, as well as previously working as an investigator for the U.S. FDA.

Mr. Jensen has designed, built and implemented quality systems from scratch for start-up companies as a single-person QA department, and has also led Quality teams of up to 90 people. He has extensive experience with regulatory inspections, including directly hosting inspections from different health authorities; performing inspection readiness activities and mock inspections; delivering inspection training to company and investigator site staff; and conducting BIMO and GMP inspections while working for the FDA. Within the CRO space, Mr. Jensen has managed teams across the following functions: quality risk management; global audits; vendor management; CAPA; audit and inspection defense; policy and procedure management; billable audits; and quality analytics.